GC Biopharma sells entire Curevo stake to Eli Lilly for KRW 460 billion, boosting financial resources for new business and shareholder value
GC Biopharma decided to sell its entire stake (21,075,336 shares, 100%) in Curevo, Inc. to Eli Lilly and Company. Total consideration is approximately KRW 459.9 billion (upfront payment KRW 306.6 billion, milestone payment KRW 153.3 billion), with external valuation by Hanul Accounting Corporation confirming the price is within a fair range using DCF method.
The purpose is to secure funds for new business investments. The massive cash inflow (approx. KRW 460 billion) will improve financial structure and provide capacity for new investments. Additional milestone payments (KRW 153.3 billion) are contingent on achieving future sales targets.
No equity dilution occurs from this sale. The cash proceeds represent monetization of assets, positively impacting short-term shareholder value. However, there is an opportunity cost from forgoing Curevo's future growth potential.
[AI Comprehensive Analysis]This stake sale is a positive event as GC Biopharma monetizes its asset at a fair price to secure new business investment funds. While it improves financial health and shareholder value in the short term, potential opportunity cost may arise from Curevo's future performance.
KOSPI Filing Information
Filing: Report on Major Facts (Decision to Transfer Stocks and Investment Securities of Other Corporations)